All articles by Srivani Venna

1. Lilly launches trial to examine selpercatinib in NSCLC patients

   Eli Lilly and Company has launched the LIBRETTO-431 Phase III clinical trial (NCT04194944) to examine selpercatinib (LOXO-292) for treatment-naïve RET…
   Read More…

   12 Dec
2. AstraZeneca and Daiichi Sankyo report positive cancer drug trial data

   AstraZeneca and Daiichi Sankyo have reported that experimental breast cancer drug trastuzumab deruxtecan (DS-8201) halted cancer in women who had…
   Read More…

   12 Dec
3. ProQR doses first patient in Aurora trial of retinal disease therapy

   ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with…
   Read More…

   12 Dec
4. Sanofi’s trial of sutimlimab meets primary and secondary endpoints

   The open-label, single-arm CARDINAL trial evaluated the safety and efficacy of the novel investigational C1s inhibitor and met its primary…
   Read More…

   11 Dec
5. Amgen reports positive data in multiple myeloma study

   Amgen has reported that the primary analysis of the Phase III CANDOR study of Kyprolis in combination with dexamethasone and…
   Read More…

   11 Dec
6. Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL

   Daiichi Sankyo has dosed the first patient in a Phase II study to evaluate the efficacy and safety of valemetostat…
   Read More…

   11 Dec
7. Abeona to initiate Phase III trial of EB-101 to treat RDEB

   The move comes after the US Food and Drug Administration (FDA) removed its clinical hold and provided clearance for the…
   Read More…

   10 Dec
8. Bristol-Myers and bluebird report positive data from myeloma study

   bb21217 is an investigational BCMA-targeted chimeric antigen receptor (CAR) T cell therapy being evaluated to treat patients with R/RMM. The…
   Read More…

   10 Dec
9. Knopp to start trial enrollment of oral dexpramipexole in H1 2020

   Under the Phase II, randomised, double-blind, placebo-controlled trial, oral eosinophil-lowering drug candidate dexpramipexole will be tested as a pre-biologic alternative…
   Read More…

   3 Dec
10. Opthea to raise $33m for retinal eye disease development

    The company will issue 18.9 million shares at A$2.65 per share to sophisticated and institutional investors in Australia and the…
    Read More…

    2 Dec